Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 138.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 49,435 shares of the company’s stock after buying an additional 28,725 shares during the quarter. Profund Advisors LLC’s holdings in Amylyx Pharmaceuticals were worth $1,439,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Amylyx Pharmaceuticals in the second quarter valued at approximately $158,534,000. Jupiter Topco LLC bought a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $94,014,000. Siren L.L.C. bought a new stake in shares of Amylyx Pharmaceuticals during the first quarter valued at approximately $17,097,000. Alyeska Investment Group L.P. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $18,912,000. Finally, Almitas Capital LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $17,509,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ AMLX opened at $28.04 on Tuesday. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $10.83 and a fifty-two week high of $41.14. The firm’s 50-day simple moving average is $30.68 and its 200 day simple moving average is $20.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMLX. Guggenheim increased their target price on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Citigroup boosted their price target on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $40.71.

Insider Buying and Selling

In related news, Director M Jr sold 30,000 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $27.70, for a total transaction of $831,000.00. Following the transaction, the director owned 782,881 shares of the company’s stock, valued at $21,685,803.70. The trade was a 3.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James Frates sold 10,810 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total value of $349,811.60. Following the sale, the chief financial officer owned 233,625 shares of the company’s stock, valued at $7,560,105. This trade represents a 4.42% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 60,374 shares of company stock worth $1,815,257 over the last three months. Company insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Company Profile